Kingy AI
For AI Companies

Breakthrough Tracker record

The FDA approved the first treatment that directly restores orexin signaling in narcolepsy type 1

The FDA approved Orzeyful (oveporexton) for adults with narcolepsy type 1 after two randomized, double-blind, placebo-controlled 12-week studies enrolling 273 adults. It is the first approved medicine to act directly on the lost orexin-signaling pathway and address the disorder’s full symptom range.

← Back to the filtered Breakthrough Tracker

Stable ID
medicine-orzeyful-orexin-narcolepsy-approval-2026
Revision
medicine-orzeyful-orexin-narcolepsy-approval-2026.v1
Field
Medicine · Sleep medicine and neuropharmacology
Evidence
Tier 1 · Peer reviewed: No full phase 3 paper located
Record state
Current · FDA approved
Last checked

AI role

No substantive AI role was disclosed in the FDA decision or inspected trial records.

Record details

Problem or result
Disease-mechanism-directed treatment for adult narcolepsy type 1
Authors
FDA review teams; FirstLight and RadiantLight investigators
Institutions
U.S. Food and Drug Administration; Takeda; multinational phase 3 sites
Result date
FDA approval August 5, 2026

Why it matters

Existing medicines treated separate symptoms. Oveporexton is the first approved oral orexin-2 receptor agonist intended to restore the missing wakefulness signal underlying narcolepsy type 1.

Limits

Approval is for adults with narcolepsy type 1, not narcolepsy type 2 or a cure. The pivotal studies lasted 12 weeks; insomnia and urinary effects were common, strong CYP3A inhibitors are contraindicated, pediatric safety is unestablished, and marketing awaits DEA scheduling.

Sources

  1. Regulator: FDA approval announcement for Orzeyful
  2. Regulator: FDA 2026 novel-drug approvals register
  3. Primary: CHEST phase 3 FirstLight and RadiantLight trial abstract
  4. Independent: ICER evidence review of oveporexton for narcolepsy

Correction and revision history

  1. 2026-08-22 — Added after primary-source, scope, status, AI-role and limitation review.

Machine-readable: JSON v1 · CSV v1 · Schema v1

This individual record remains noindex until a story-specific featured image passes Kingy’s rendered-pixel visual review. The source-linked tracker hub remains the public index.